A Phase 1 Study of Mosliciguat in Healthy, Adult Males

Phase 1 Completed 8 enrolled Pulmovant, Inc.

Non-randomizedSequentialOpen-labelOther

Summary

This is a single-center, Phase 1, open-label, 3-period, fixed-sequence study to investigate the bioavailability, absorption, metabolism, excretion and the safety of mosliciguat administered to healthy male adults.

Timeline

Start: 2025-06-10
Primary completion: 2025-06-30
Completion: 2025-07-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mosliciguat	Unknown	—	Inhaled

Indications

No indication recorded.